Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C H Polman

Showing results (221-230 of 290) with videos related to

Pageof 29
Sort By:
Neurology|December 1, 1996
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2B W van Oosten, F Barkhof, L Truyen, et al.
Annals of Neurology|October 12, 2000
Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosisB A de Jong, H M Schrijver, T W Huizinga, et al.
Neurology|January 29, 2003
Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophyM J Eikelenboom, A Petzold, R H C Lazeron, et al.
Neurology|October 27, 2004
CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosisK Rejdak, M J Eikelenboom, A Petzold, et al.
Neurology|August 18, 2006
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromesL Kappos, C H Polman, M S Freedman, et al.
Neurology|January 6, 2012
Postmortem verification of MS cortical lesion detection with 3D DIRA Seewann, E-J Kooi, S D Roosendaal, et al.
Journal of Neurology|June 1, 1996
Quality of life in multiple sclerosis: the disability and impact profile (DIP)G J Lankhorst, F Jelles, R C Smits, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 3, 2010
Cerebrospinal fluid ATP metabolites in multiple sclerosisG Lazzarino, A M Amorini, M J Eikelenboom, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 1, 2005
Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosisR H C Lazeron, J B Boringa, M Schouten, et al.
Annals of Neurology|August 1, 1992
The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over studyH A van Diemen, C H Polman, T M van Dongen, et al.
Pageof 29

Showing results (221-230 of 290) with videos related to

Sort By:
Pageof 29
Neurology|December 1, 1996
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2B W van Oosten, F Barkhof, L Truyen, et al.
Annals of Neurology|October 12, 2000
Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosisB A de Jong, H M Schrijver, T W Huizinga, et al.
Neurology|January 29, 2003
Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophyM J Eikelenboom, A Petzold, R H C Lazeron, et al.
Neurology|October 27, 2004
CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosisK Rejdak, M J Eikelenboom, A Petzold, et al.
Neurology|August 18, 2006
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromesL Kappos, C H Polman, M S Freedman, et al.
Neurology|January 6, 2012
Postmortem verification of MS cortical lesion detection with 3D DIRA Seewann, E-J Kooi, S D Roosendaal, et al.
Journal of Neurology|June 1, 1996
Quality of life in multiple sclerosis: the disability and impact profile (DIP)G J Lankhorst, F Jelles, R C Smits, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 3, 2010
Cerebrospinal fluid ATP metabolites in multiple sclerosisG Lazzarino, A M Amorini, M J Eikelenboom, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 1, 2005
Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosisR H C Lazeron, J B Boringa, M Schouten, et al.
Annals of Neurology|August 1, 1992
The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over studyH A van Diemen, C H Polman, T M van Dongen, et al.
Pageof 29